AE Wealth Management LLC Acquires 5,692 Shares of IDEXX Laboratories, Inc. $IDXX

AE Wealth Management LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 96.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,597 shares of the company’s stock after purchasing an additional 5,692 shares during the quarter. AE Wealth Management LLC’s holdings in IDEXX Laboratories were worth $6,220,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new stake in IDEXX Laboratories in the second quarter worth about $29,000. Ameritas Advisory Services LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. NewSquare Capital LLC grew its stake in shares of IDEXX Laboratories by 87.5% during the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after acquiring an additional 35 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the period. Finally, WPG Advisers LLC purchased a new stake in IDEXX Laboratories in the 1st quarter worth approximately $37,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 2,187 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the transaction, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Down 0.7%

Shares of IDEXX Laboratories stock opened at $708.45 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $735.00. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The business has a 50-day moving average price of $645.28 and a 200-day moving average price of $580.40. The firm has a market cap of $56.57 billion, a price-to-earnings ratio of 58.99, a PEG ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of several analyst reports. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. UBS Group raised their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.